Corporate News – Market Update
Kyntra Bio (KYNB)
- Traded down 1.33 % during a 24‑hour period ending at 04:21 PM Central Europe on Thursday 22 Oct 2026.
- Current share price: USD 5.34 on major exchanges.
- Shares outstanding: 4 million.
- Market capitalization: USD 21.4 million.
- Volume traded in the last 24 hours: USD 61.5 k.
- Since the end of the previous month, the stock has declined 28.43 %.
- 200‑day simple moving average: USD 7.26.
- 52‑week high: USD 11.39 (07 Nov 2025).
- 52‑week low: USD 4.85 (16 Oct 2026).
Related stocks – 24‑hour performance
| Ticker | % Change | Current Price (USD) | Market Cap (USD m) | Notes |
|---|---|---|---|---|
| ATCH – Atlasclear | –1.83 % | 0.16 | 24.6 | – |
| QRHC – Quest Resource | –1.68 % | 1.15 | 25.1 | – |
| NXTC – Nextcure | –0.46 % | 5.35 | 24.9 | – |
| IGC – IGC Pharma | –4 % | 0.25 | 25.3 | Recent proxy statement highlights Phase 2 CALMA trial progress, patent grants, AI platform advancements, and financial adjustments to improve cash flow. |
| ATOS – Atossa Therapeutics | –0.39 % | 2.65 | 24.9 | – |
Company background FibroGen, Inc. is a research‑oriented pharmaceutical company focused on developing innovative therapeutic agents for unresolved medical needs. The company operates within the Health Care sector, specifically in the Biotechnology industry.